Pharvaris is a clinical-stage company developing novel, oral bradykinin B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, building on its deep-seated roots in HAE. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically.

Deucrictibant is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist.

PHVS416 is an investigational softgel capsule formulation containing deucrictibant. PHVS416 is designed to provide rapid and reliable symptom relief, through rapid exposure of attack-mitigating therapy in a convenient, small oral dosage form. In a Phase 2 study, PHVS416 demonstrated consistent positive results across all endpoints and assessments, supporting the efficacy and tolerability profile of PHVS416 in treating HAE attacks. PHVS416 is currently in Phase 2 clinical development outside the U.S. for the on-demand and proof-of-concept prophylactic treatment of HAE.

PHVS719 is an investigational extended-release tablet formulation containing deucrictibant. PHVS719 is designed to prevent HAE attacks in a convenient, small oral dosage form. PHVS719 is currently in Phase 1 clinical development for the prophylactic treatment of HAE. In healthy volunteers, a single dose of PHVS719 was well tolerated with an extended-release profile supporting once-daily dosing.

Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.